🔎 Trials Near Me

Akèy › Kansè Ezofajyen › Texas › Dallas

Etid klinik pou Kansè Ezofajyen nan Dallas, TX

11 etid pou Kansè Ezofajyen ap chèche patisipan nan sit nan ak bò kote Dallas (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

DESTINY-PANTUMOUR04

Ap rekriteEtid obsèvasyon
  • Research Site, Dallas
Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Ap rekriteFaz 1/2
  • Baylor, Scott and White Research Institute, Dallas
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Ap rekriteFaz 1
  • Texas Oncology - DFW (Sammons CC), Dallas
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07114601

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Ap rekriteFaz 1
  • Texas Oncology - DFW (Sammons CC), Dallas
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213791

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Ap rekriteEtid obsèvasyon
  • UT Southwestern Medical Center, Dallas
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444

Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer

Ap rekriteFaz 1
  • University of Texas Southwestern Medical Center, Dallas
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07700420

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Ap rekriteFaz 1/2
  • Texas Oncology, Dallas
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT03526835

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Ap rekriteFaz 2
  • Texas Oncology - DFW, Dallas
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT06695845

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Ap rekriteEtid obsèvasyon
  • Massive Bio SYNERGY-AI site, Dallas
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774

Etid Kansè Ezofajyen nan lòt vil

Lòt etid nan Dallas

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.